B. Rabault

Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective study

John B. Porter, Renzo Galanello, Giuseppe Saglio et al. · European Journal Of Haematology · 2007 · 239 citations · Full text

Correction of anemia in a transfusion‐dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade<b>^®</b>, ICL670)

Anna Angela Di Tucci, Roberta Murru, Daniele Alberti et al. · European Journal Of Haematology · 2007 · 63 citations · Full text

Anemia, Hematological Malignancy, Transplantation +14

Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.

Aitana Calvo, Heikki Joensuu, Martin Sebastian et al. · Journal of Clinical Oncology · 2018 · 42 citations

Tumor-associated Macrophages, Breast Oncology, Antitumor Activity +16

A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.

John B. Porter, Elliott Vichinsky, Christian Rosé et al. · Blood · 2004 · 30 citations

Mode of action of the antitumor compound girodazole (RP 49532A, NSC 627434)

Geneviève Colson, B. Rabault, François Lavelle et al. · Biochemical Pharmacology · 1992 · 29 citations

Molecular Pharmacology, Medicinal Chemistry, Rp 49532A +14